

PeriVision partners with distributor Von Hoff to serve Swiss & Liechtenstein markets

Lausanne, Switzerland – August 8, 2024.

[PeriVision](#), an innovative spin-off from the University of Bern and the University Hospital Bern, announces that it has entered into a distribution agreement with [Von Hoff](#), a leading ophthalmic medical device distributor in Switzerland and Liechtenstein, to commercialize the VisionOne VR eye testing platform with an initial focus on visual field testing for glaucoma.



Picture: VisionOne combines VR headsets and AI into the next generation systems for vision testing.

This collaboration is a wonderful milestone for eye care in Switzerland, where glaucoma is one of the most common causes of blindness. Two out of every hundred people aged 40 and over suffer from glaucoma, 50,000 Swiss people are known to suffer from glaucoma caused by increased intraocular pressure, 10 percent of whom are at risk of blindness. However, the Swiss Ophthalmological Society (SOG) points out that the number of unreported cases in this area is very high. It is assumed that a total of around 100,000 people in Switzerland are affected by glaucoma. Therefore, innovative ways to diagnose and monitor the condition are needed to address this unmet clinical need.

Benedetto Sgroi, PeriVision's Chief Commercial Officer (CCO), commented on the deal:

"This is a fantastic milestone! Partnering with a leading company like Von Hoff shows that PeriVision's product has a bright future and addresses a growing need for more efficient and patient-friendly ophthalmic equipment in Swiss practices and clinics. We look forward to the partnership and serving many doctors and patients together."

Lukas Eigenmann, CEO of VON HOFF talked about the incredible opportunity to bring an innovative product to the market:

"Von Hoff has been at the forefront of innovation for the last 70 years and we are very excited to now bring PeriVision's innovative VisionOne platform to the Swiss eye care market."



Von Hoff and PeriVision will jointly exhibit at the Swiss Ophthalmology Congress (SOG) from August 28 - 30 in St. Gallen, Switzerland, and invite you to come by their booths to learn more about VisionOne and PeriVision's clinical research. For more information about PeriVision, please visit www.perivision.com or contact info@perivision.com.